Looking Into the 'Rich' Biosimilar Landscape with Cate Lockhart of BBCIC | Asembia Specialty Pharmacy Summit
Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, shared results yesterday of a survey that look at biosimilars on the pharmacy benefit side of coverage versus medical benefit. The survey also shared how payers and those on the pharmaceutical side are anticipating the introduction of Adalimumab (Humira®), as well as what to look for in the future of the biosimilar pipeline.
Data revealing the concerns and plans of payers and formulary managers was the highlighted topic of discussion during a session yesterday co-presented by Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium.
Conducted in a survey, the data shared the anticipation of Adalimumab (Humira®) and looked at biosimilars on a pharmacy benefit side of coverage versus medical benefit. These results were presented by Lockhart and others at the Asembia 2023 Specialty Pharmacy Summit in Las Vegas.
Expressing the future of the biosimilars pipeline is "quite rich," Lockhart said payers have been pretty comfortable with them and are actively looking at ways to incorporate them.
Though, there are some questions concering biosimilars when it comes to operationalizing coverage.
To take a deeper dive into Lockhart's discussion, watch our interview above.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
